Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biovail Generic Adalat May Be Sublicensed Under Pending FTC Settlement

Executive Summary

Biovail may sublicense Elan's generic version of Bayer's Adalat CC under a pending settlement with the Federal Trade Commission

You may also be interested in...

FTC/Biovail Tiazac Settlement Blocks Royalties From Andrx On Generic

The Federal Trade Commission consent order with Biovail regarding Tiazac voids a proposed settlement between the company and Andrx

FTC To Testify On Generic Reform; Agency Report May Be “Months” Away

Patent licensing deals that relate exclusively to listing in FDA's "Orange Book" will attract antitrust scrutiny, FTC Office of Policy Planning Director Ted Cruz said

Biovail/Elan FTC Settlement: Elan Generic Adalat To Switch Distributors

Elan plans to launch its generic version of Bayer's Adalat CC through a new distributor following a settlement with the Federal Trade Commission




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts